Efficacy News and Research

RSS

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

CTI BioPharma Corp. today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program.

16 Mar 2015

Combined use of enalapril and folic acid can significantly reduce risk of first stroke

In a study that included more than 20,000 adults in China with high blood pressure but without a history of stroke or heart attack, the combined use of the hypertension medication enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the American College of Cardiology Annual Scientific Session.

16 Mar 2015

Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

Treating respiratory disease is often difficult because drugs have to cross biological barriers such as respiratory tissue and mucosa, and must therefore be given in large quantities in order for an effective amount to reach the target.

13 Mar 2015

'Turbocharged' protein holds promise in hemophilia gene therapy

Using gene therapy to produce a mutant human protein with unusually high blood-clotting power, scientists have successfully treated dogs with the bleeding disorder hemophilia, without triggering an unwanted immune response.

13 Mar 2015

CannTrust, Canabo to partner on medical marijuana research project

CannTrust, Canada's only pharmacist-controlled licensed producer and distributor of medical cannabis today announced a collaboration with Canabo Medical Corporation to partner on a research project on marijuana for medical purposes.

12 Mar 2015

Ember Therapeutics, Mariel Therapeutics sign definitive merger agreement

Ember Therapeutics, Inc., a Boston-based biotechnology company dedicated to the discovery and development of novel obesity and diabetic related therapies, and Mariel Therapeutics, a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis and kidney fibrosis using Bone Morphogenetic Protein (BMP)-7, jointly announce today that they have entered into a definitive agreement to merge the two companies.

12 Mar 2015

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.

12 Mar 2015

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of a definitive licensing and development agreement with MultiCell Immunotherapeutics, Inc. concerning the development of certain antibody-drug conjugates (ADCs).

12 Mar 2015

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families.

12 Mar 2015

McGill researchers discover that lots of useful medical information getting lost

Lots of potentially useful medical information is getting lost. McGill researchers discovered this when they looked into the lack of reporting of information from "stalled drug" trials in cancer, cardiovascular and neurological diseases.

12 Mar 2015

Organ-on-a-chip could replace use of animals to test drugs for safety and efficacy

When University of California, Berkeley, bioengineers say they are holding their hearts in the palms of their hands, they are not talking about emotional vulnerability.

12 Mar 2015

Yoga could help reduce depression in pregnant women

In a small pilot study, researchers at Brown University, Butler Hospital, and Women & Infants' Hospital have found evidence suggesting that yoga could help pregnant women with significant depression reduce the severity of the mood disorder.

12 Mar 2015

Sanford-Burnham researchers discover control mechanism for glutamine uptake in breast cancer cells

Researchers at Sanford-Burnham Medical Research Institute have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy.

11 Mar 2015

LSDF announces new Matching grants to promote treatments for devastating medical conditions

The Life Sciences Discovery Fund today announced nearly $1 million in Matching grants to two Washington-based companies to promote translation of promising treatments for devastating medical conditions from the laboratory to the commercial marketplace.

11 Mar 2015

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

10 Mar 2015

GOJO Industries joins NPSF to educate, gain awareness for critical importance of patient safety

United in Safety is the theme of Patient Safety Awareness Week, led by the National Patient Safety Foundation, March 8 – March 14, 2015. GOJO Industries, a leader in hand hygiene and skin health and inventors of PURELL Hand Sanitizer, is joining the NPSF and hospitals across the United States to educate and gain awareness for the critical importance of patient safety.

10 Mar 2015

Scientists find blood-based genomic biomarkers that could help identify young boys with ASD

In a study published in the current online issue of JAMA Psychiatry, an international team of scientists, led by researchers at the University of California, San Diego School of Medicine, report finding a highly accurate blood-based measure that could lead to development of a clinical test for autism spectrum disorder (ASD) risk in males as young as one to two years old.

10 Mar 2015

BMC researchers to play key role in examining best treatment for acute low back pain

Boston Medical Center researchers are part of a national clinical trial that will examine how best to treat acute low back pain and potentially prevent it from being chronic. BMC will receive $2.3 million for its role in the five-year study that was recently approved for a $14 million award by the Patient-Centered Outcomes Research Institute.

9 Mar 2015

Phico Therapeutics gets £2.25M Translation Award to develop SASPject PT4 antibiotic for E. coli, K. pneumoniae

Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25M Translation Award by the Wellcome Trust to develop its SASPject PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae.

9 Mar 2015

Scientists design a promising vaccine for herpes viruses

Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine.

9 Mar 2015

Efficacy News and Research

Results of pacritinib Phase 2 study in myelofibrosis patients published in journal 'Blood'

Combined use of enalapril and folic acid can significantly reduce risk of first stroke

Antibiotic nanoparticles can help treat lung infection, prevent drug resistance

'Turbocharged' protein holds promise in hemophilia gene therapy

CannTrust, Canabo to partner on medical marijuana research project

Ember Therapeutics, Mariel Therapeutics sign definitive merger agreement

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Oxis Biotech executes licensing agreement with MCIT for development of antibody-drug conjugates

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

McGill researchers discover that lots of useful medical information getting lost

Organ-on-a-chip could replace use of animals to test drugs for safety and efficacy

Yoga could help reduce depression in pregnant women

Sanford-Burnham researchers discover control mechanism for glutamine uptake in breast cancer cells

LSDF announces new Matching grants to promote treatments for devastating medical conditions

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

GOJO Industries joins NPSF to educate, gain awareness for critical importance of patient safety

Scientists find blood-based genomic biomarkers that could help identify young boys with ASD

BMC researchers to play key role in examining best treatment for acute low back pain

Phico Therapeutics gets £2.25M Translation Award to develop SASPject PT4 antibiotic for E. coli, K. pneumoniae

Scientists design a promising vaccine for herpes viruses

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News